CD8A and neoplasm: Altogether, these findings demonstrate that combined targeting of CD47 and PD‐L1 via CD47 × PD‐L1 BisAb is an effective treatment for controlling AT3‐OVA breast cancer and is superior to anti‐PD‐L1 monotherapy for promoting robust CD8+ T‐cell responses within the tumor.